Continuous_intratumoral_infusion_of_methotrexate_for_recurrent_glioblastoma:_a_pilot_study._Five_patients_with_documented_recurrences_of_glioblastoma_multiforme_were_given_continuous_infusions_of_methotrexate_delivered_intratumorally_using_implantable_catheters_and_subcutaneous_refillable_pumps._A_continuous_infusion_of_methotrexate_(1_mg/d)_was_begun_with_concomitant_oral_administration_of_folinic_acid._The_methotrexate_dose_was_increased_every_2_weeks_to_3,_10,_30,_and,_ultimately,_75_mg/d_in_two_patients._Samples_of_serum_and_ventricular_cerebrospinal_fluid_(CSF)_were_obtained_to_determine_the_levels_of_methotrexate_and_total_bioactive_folates,_and_brain_tissue_was_obtained_from_two_patients_for_determination_of_methotrexate_concentration._The_patients_survived_from_7_to_49_weeks_after_the_implantation_of_the_infusion_device._Neither_the_clinical_examination_nor_sequential_radiological_studies_gave_clear_evidence_of_reduction_in_tumor_size._Pneumonia_developed_in_one_patient,_and_mild_hepatitis_and_increased_seizure_frequency_in_another._Methotrexate_was_stable_in_the_delivery_system_over_12_days,_and_ventricular_CSF_reached_steady-state_levels_by_5_days._Steady-state_ventricular_CSF_levels_of_methotrexate_were_higher_than_serum_levels_in_some_patients,_while_the_reverse_was_true_in_others._Levels_of_total_bioactive_folates_in_the_CSF_did_not_increase_above_the_normal_range._Methotrexate_concentrations_were_highest_at_the_center_of_the_tumor,_but_measurable_amounts_of_methotrexate_were_detectable_in_all_areas_of_the_brain._At_autopsy_in_four_patients,_variable_liquefactive_necrosis_of_the_brain_tumors_was_seen,_and_viable_tumor_was_found_at_the_periphery_of_the_tumor_bed._These_preliminary_results_suggest_that_it_is_technically_feasible_to_infuse_methotrexate_into_brain_tumor_cavities,_and_show_that_little_central_nervous_system_or_systemic_toxicity_was_encountered_in_five_patients._Better_delineation_of_the_safety_and_efficacy_of_this_therapeutic_approach_will_require_further_clinical_trials.